Scalper1 News
Over the last four years, life for multiple-sclerosis patients has changed for the better as a new generation of powerful oral drugs has moved into a market dominated by injectables. But things aren’t done changing yet, as a September conference in Boston showed. At the meeting, held jointly by the American and European Committees for Treatment and Research in MS, the star presentation came from small biotech Receptos (RCPT). The phase-two Scalper1 News
Scalper1 News